FDA Requires GLP-1 RA Safety Labeling Changes for a Potential NAION Risk (Nov 9, 2026)

Biohacking Elite logo

Published by Biohacking Elite · Updated November 13, 2026. No independent specialist review is claimed.

On November 9, 2026, FDA required safety labeling changes for all GLP-1 RA medications because of a potential increased risk of NAION, a rare eye condition that can cause sudden vision loss in one eye. This is a labeling change for approved drugs, not a withdrawal, and not a finding about research peptides.

What this action is

The official Drug Safety Communication directs application holders for glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications to add information to the Warnings and Precautions section of labeling. FDA describes non-arteritic anterior ischemic optic neuropathy (NAION) as a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss. FDA describes GLP-1 RAs as approved medications used to treat type 2 diabetes or to reduce excess body weight and maintain weight reduction, with additional approved uses in adults for certain drugs in the class, including some cardiovascular, kidney, obstructive sleep apnea, and metabolic dysfunction-associated steatohepatitis indications.

FDA’s table of FDA-approved GLP-1 RAs includes exenatide (Byetta, 2005; FDA notes the Byetta application was later withdrawn and only generic exenatide products are marketed), liraglutide (Victoza, Saxenda, and in Xultophy), dulaglutide (Trulicity), lixisenatide plus insulin glargine (Soliqua), semaglutide (Ozempic, Rybelsus, Wegovy), tirzepatide (Mounjaro, Zepbound), and orforglipron (Foundayo, 2026). FDA notes that tirzepatide is a GIP receptor and GLP-1 receptor agonist.

FDA reports a meta-analysis of 126 randomized, controlled trials in 134,253 patients. It identified 15 probable NAION events: 10 with GLP-1 RAs, 5 with placebo, and none with other non-GLP-1 RA glucose-lowering medication. The stated incidence is 6.4 events per 100,000 person-years with GLP-1 RAs, compared with 3.8 in comparator-treated patients. FDA also cites published literature putting general-population NAION incidence at 2.3 to 10.2 cases per 100,000 persons per year in adults older than 50.

In FDA’s Sentinel study of adults with type 2 diabetes who started a GLP-1 RA, an SGLT-2 inhibitor, or a DPP-4 inhibitor between 2019 and 2024, incidence rates ranged from 26 to 32 events per 100,000 person-years. FDA reports no statistically significant increase versus SGLT-2 inhibitors (hazard ratio 1.19, 95% confidence interval 0.91 to 1.54) and an increased risk versus DPP-4 inhibitors (hazard ratio 1.43, 95% confidence interval 1.02 to 2.01). FDA says NAION cases have been reported for all currently marketed GLP-1 RA products, and that it concluded there is a potential increased risk of rare NAION events. It also states that it began a further evaluation after a July 2024 article by Hathaway and colleagues, and that it identified several limitations of that study.

What this action is not

This is not a recall or a decision to remove GLP-1 RA medications from the market. It is not medical advice from Biohacking Elite, and this summary does not tell anyone to start, stop, or change a medication. FDA tells patients to contact a health care professional right away if they have symptoms of NAION, which it lists as sudden, painless vision loss in one eye, visual defects, color distortion, or reduced central sharpness.

The communication is about FDA-approved GLP-1 RA medications. It is not an assessment of research-use peptides, compounded preparations, or unapproved laboratory materials. Biohacking Elite is summarizing the official notice for documentation context only.

Source: FDA Drug Safety Communication, November 9, 2026.

Related verification resources

These official notices concern specific regulator findings and policies. They are not tests of Biohacking Elite’s research-use-only catalog. For a buyer-facing workflow that checks a certificate with the issuing laboratory, and for how to read test-scope claims, start here:

For additional research context, see the research library.


About this resource

Biohacking Elite — company editorial resource for laboratory research and documentation literacy. This page summarizes official regulator documents for context. It is not legal advice, medical advice, or a laboratory report, and it is not an endorsement of any compounded, approved, or unapproved drug product.

Research-use only. No medical advice, dosing, administration instructions or human-use recommendations are provided. Nothing here establishes that a research material is suitable for human or animal consumption, or that it is a compounded or approved drug.

For laboratory research use only. Not for human or veterinary use.
Scroll to Top